MedTrace Logo

Atezolizumab in Large Cell Neuroendocrine Carcinoma

NCT06049966 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-09-22

No results posted yet for this study

Summary

Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare and aggressive form of cancer that presents significant challenges regarding treatment options and prognosis. In this trial, the effectiveness of Atezolizumab in treating metastatic LCNEC was evaluated. Atezolizumab is an anti-PD-L1 antibody that has shown promising results in other types of cancer, such as small-cell lung Cancer and non-small-cell lung cancer. The trial aimed to assess the efficacy and safety of atezolizumab in combination with chemotherapy as a potential treatment option for treatment-naive patients with metastatic LCNEC The trial was conducted as an open-label, non-randomized study, comparing Atezolizumab plus platinum etoposide to platinum etoposide alone in patients with metastatic LCNEC.

Conditions

  • Large Cell Neuroendocrine Carcinoma of the Lung

Interventions

DRUG

Atezolizumab

TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML

DRUG

Carboplatin

SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML

DRUG

Etoposide

ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML

Sponsors & Collaborators

  • Oncology Center of Biochemical Education And Research

    lead OTHER

Principal Investigators

  • Konstantinos N Syrigos · National and Kapodistrian University of Athens

  • Georgios Evangelou · National and Kapodistrian University of Athens

  • Konstantinos N Syrigos · Konstantinos

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2022-08-01
Completion
2023-05-01
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06049966 on ClinicalTrials.gov